CandlesenseCandlesense
News/Companies/ERNA

ERNA News

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

ERNA

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO).

January 27, 2026
Read more →

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

ERNA

(NASDAQ:ERNA) CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8–10, 2025.

September 3, 2025Conference
Read more →

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

ERNA

June 12, 2025
Read more →

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

ERNA

June 11, 2025
Read more →

Ernexa Therapeutics Announces 1-For-15 Reverse Stock Split, Effective June 12, 2025

ERNA

June 10, 2025
Read more →

Reported June 2, 2025: Ernexa Therapeutics Amends Certificate Of Incorporation To Increase Authorized Common Stock From 100M To 150M Shares

ERNA

June 3, 2025
Read more →

Ernexa Therapeutics Establishes Texas Subsidiary To Support Ongoing Development Of ERNA-101 And Future Clinical Operations

ERNA

May 14, 2025
Read more →

Rnexa Therapeutics Files Prospectus For Resale Of 10.4M Shares Of Common Stock

ERNA

April 16, 2025
Read more →

Eterna Therapeutics Changes Name to Ernexa Therapeutics

ERNA

March 25, 2025
Read more →

Eterna Therapeutics Announces Inaugural Scientific Advisory Board Meeting, Discussed ERNA-101 Preclinical Advances In Ovarian Cancer, Focused On Immune Activation, Tumor Microenvironment, Combination Therapies, And ERNA-102 For Autoimmune Diseases

ERNA

February 26, 2025
Read more →

Eterna Therapeutics Reports Preclinical Study Results On Lead Product ERNA-101 In Ovarian Cancer

ERNA

January 14, 2025
Read more →